• Jay F Piccirillo, Joshua Finnell, Anna Vlahiotis, Richard A Chole, and Edward Spitznagel.
• Division of Clinical Outcomes Research, Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, MO 63110, USA. piccirilloj@ent.wustl.edu
• Arch Otolaryngol. 2007 Apr 1; 133 (4): 390-7.

ObjectiveTo assess the therapeutic benefit of gabapentin (Neurontin) for subjective idiopathic troublesome tinnitus.DesignAn 8-week, double-blind, randomized clinical trial.SettingAcademic otolaryngology clinic in St Louis, Mo.SubjectsOne hundred thirty-five subjects with severe idiopathic subjective tinnitus of 6 months' duration or longer.InterventionGabapentin, at a maintenance dosage of 900 to 3600 mg/d for 8 weeks, or lactose placebo.Main Outcome MeasureChange in the Tinnitus Handicap Inventory score from baseline to the study end point.ResultsThe overall change in the Tinnitus Handicap Inventory score for the entire cohort from baseline to week 8 was 11.2; the change among the 59 subjects randomized to the gabapentin arm was 11.3 and the change among the 56 subjects in the placebo arm was 11.0. The difference was 0.03 (95% confidence interval, -5.5 to 6.2; P = .91).ConclusionGabapentin is no more effective than placebo for the relief of idiopathic subjective tinnitus.Trial Registrationclinicaltrials.gov Identifier: NCT00317850.

20 keywords...

hide…